Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Nonmyeloablative
100%
Follicular Lymphoma
100%
Autologous Transplantation
100%
Graft-versus-host Disease (GvHD)
30%
Rituximab
20%
MD Anderson Cancer Center
10%
Cyclophosphamide
10%
Overall Survival
10%
Medicare Reimbursement
10%
Survivors
10%
Progression-free Survival
10%
Relapse Rate
10%
Non-relapse Mortality
10%
Etoposide
10%
Fludarabine
10%
Carmustine
10%
Houston
10%
Cytarabine
10%
Melphalan
10%
Myelodysplasia
10%
Group 15 Elements
10%
Bendamustine
10%
Donor Availability
10%
Medicine and Dentistry
Transplantation
100%
Follicular Lymphoma
100%
Stem Cell Transplant
100%
Rituximab
20%
Acute Graft Versus Host Disease
20%
Malignant Neoplasm
10%
Cyclophosphamide
10%
Medicare
10%
Overall Survival
10%
Survival Rate
10%
Progression Free Survival
10%
Recurrence Risk
10%
Cytarabine
10%
Myelodysplastic Syndrome
10%
Fludarabine
10%
Conditioning
10%
Etoposide
10%
Carmustine
10%
Chronic Graft Versus Host Disease
10%
Melphalan
10%
Bendamustine
10%